Erratum: Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment (Breast Cancer Research and Treatment DOI: 10.1007/s10549-011-1753-2);Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 201-214

  Pohorelic, Brant ^a   Singh, R ^a   Parkin, S ^a   Koro, K ^a   Yang, A D ^a   Egan, C ^a   Magliocco, A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bone metastasis; Breast cancer; In vitro co culture system; Src kinase; Tumor microenvironment

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; PROTEIN TYROSINE KINASE; SARACATINIB; SMALL INTERFERING RNA;

ARTICLE; BONE CELL; BONE METASTASIS; BREAST CANCER; BREAST CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; COCULTURE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR MICROENVIRONMENT;

EID: 84860349155     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1797-3     Document Type: Erratum

References (99)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin. doi: 10.3322/caac.20107
2. RE Coleman RD Rubens 1987 The clinical course of bone metastases from breast cancer Br J Cancer 55 1 61 66 3814476 10.1038/bjc.1987.13 1:STN:280:DyaL2s7ivVOmug%3D%3D (Pubitemid 17234155)
3. RE Coleman P Smith RD Rubens 1998 Clinical course and prognostic factors following bone recurrence from breast cancer Br J Cancer 77 2 336 340 9461007 10.1038/bjc.1998.52 1:STN:280:DyaK1c7itV2jtw%3D%3D (Pubitemid 28029553)
4. E Fokas R Engenhart-Cabillic K Daniilidis F Rose HX An 2007 Metastasis: the seed and soil theory gains identity Cancer Metastasis Rev 26 3-4 705 715 10.1007/s10555-007-9088-5 17786535 10.1007/s10555-007-9088-5 (Pubitemid 350115118)
5. GR Mundy 2002 Metastasis to bone: causes, consequences, and therapeutic opportunities Nat Rev Cancer 2 8 584 593 10.1038/nrc867 12154351 10.1038/nrc867 1:CAS:528:DC%2BD38XlslGqsLo%3D (Pubitemid 37328925)
6. SA Rabbani AP Mazar 2007 Evaluating distant metastases in breast cancer: from biology to outcomes Cancer Metastasis Rev 26 3-4 663 674 10.1007/s10555-007-9085-8 17823779 10.1007/s10555-007-9085-8 (Pubitemid 350115115)
7. S Paget 1889 The distribution of secondary growths in cancer of the breast Canc Metastasis Rev 8 98
8. IJ Fidler 1970 Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine J Natl Cancer Inst 45 4 773 782 5513503 1:CAS:528:DyaE3cXlt1yqsrg%3D
9. IJ Fidler GL Nicolson 1977 Fate of recirculating B16 melanoma metastatic variant cells in parabiotic syngeneic recipients J Natl Cancer Inst 58 6 1867 1872 864765 1:STN:280:DyaE2s7ptVahsQ%3D%3D (Pubitemid 8123984)
10. CA Klein S Seidl K Petat-Dutter S Offner JB Geigl O Schmidt-Kittler N Wendler B Passlick RM Huber G Schlimok PA Baeuerle G Riethmuller 2002 Combined transcriptome and genome analysis of single micrometastatic cells Nat Biotechnol 20 4 387 392 10.1038/nbt0402-387 11923846 10.1038/nbt0402-387 1:CAS:528:DC%2BD38XivFWhu74%3D (Pubitemid 34286333)
11. TM Morgan PH Lange MP Porter DW Lin WJ Ellis IS Gallaher RL Vessella 2009 Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence Clin Cancer Res 15 2 677 683 10.1158/1078-0432.CCR-08-1754 19147774 10.1158/1078-0432.CCR-08-1754 1:CAS:528:DC%2BD1MXlvFequg%3D%3D
12. K Pantel G Schlimok S Braun D Kutter F Lindemann G Schaller I Funke JR Izbicki G Riethmuller 1993 Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells J Natl Cancer Inst 85 17 1419 1424 7688814 10.1093/jnci/85.17.1419 1:STN:280:DyaK3szltlGntw%3D%3D (Pubitemid 23264351)
13. S Riethdorf H Wikman K Pantel 2008 Review: biological relevance of disseminated tumor cells in cancer patients Int J Cancer 123 9 1991 2006 10.1002/ijc.23825 18712708 10.1002/ijc.23825 1:CAS:528:DC%2BD1cXht1Chs7zE
14. J Huober B Thurlimann 2010 Bone targeted therapy in breast cancer: present and future Crit Rev Oncol Hematol 74 1 S7 S10 10.1016/S1040-8428(10) 70004-4 20427030 10.1016/S1040-8428(10)70004-4
15. AA Rose PM Siegel 2010 Emerging therapeutic targets in breast cancer bone metastasis Future Oncol 6 1 55 74 10.2217/fon.09.138 20021209 10.2217/fon.09.138 1:CAS:528:DC%2BD1MXhsFyitL3N
16. I Albanese AG Scibetta M Migliavacca A Russo V Bazan RM Tomasino P Colomba M Tagliavia M La Farina 2004 Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations Biochem Biophys Res Commun 325 3 784 791 10.1016/j.bbrc.2004. 10.111 15541358 10.1016/j.bbrc.2004.10.111 1:CAS:528:DC%2BD2cXpslKgu7k%3D (Pubitemid 39487940)
17. CH Gow YL Chang YC Hsu MF Tsai CT Wu CJ Yu CH Yang YC Lee PC Yang JY Shih 2009 Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer Ann Oncol 20 4 696 702 10.1093/annonc/mdn679 19088172 10.1093/annonc/mdn679
18. NH Stoecklein CA Klein 2010 Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis Int J Cancer 126 3 589 598 10.1002/ijc.24916 19795462 10.1002/ijc.24916 1:CAS:528:DC%2BD1MXhsFGjs7nE
19. S Tortola R Steinert M Hantschick MA Peinado I Gastinger P Stosiek H Lippert W Schlegel MA Reymond 2001 Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer J Clin Oncol 19 11 2837 2843 11387355 1:CAS:528:DC%2BD3MXltVGgs7g%3D (Pubitemid 32538192)
20. E Amir WS Ooi C Simmons H Kahn M Christakis S Popovic M Kalina A Chesney G Singh M Clemons 2008 Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies Clin Oncol (R Coll Radiol) 20 10 763 768 10.1016/j.clon.2008.08.005 10.1016/j.clon.2008.08.005 1:STN:280:DC%2BD1cjisFGksw%3D%3D
21. RJ Broom PA Tang C Simmons L Bordeleau AM Mulligan FP O'Malley N Miller IL Andrulis DM Brenner MJ Clemons 2009 Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 5 1557 1562 19443366
22. Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C, Magliocco A (2010) Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration. Breast Cancer Res Treat. doi: 10.1007/s10549-010-0889-9
23. DL Wheeler M Iida EF Dunn 2009 The role of Src in solid tumors Oncologist 14 7 667 678 10.1634/theoncologist.2009-0009 19581523 10.1634/theoncologist. 2009-0009 1:CAS:528:DC%2BD1MXhtVOmtrnN
24. LC Kim L Song EB Haura 2009 Src kinases as therapeutic targets for cancer Nat Rev Clin Oncol 6 10 587 595 10.1038/nrclinonc.2009.129 19787002 10.1038/nrclinonc.2009.129
25. L Morgan RI Nicholson S Hiscox 2008 SRC as a therapeutic target in breast cancer Endocr Metab Immune Disord Drug Targets 8 4 273 278 19075780 10.2174/187153008786848295 1:CAS:528:DC%2BD1cXhsVOjtr7O
26. A Hilbig 2008 Src kinase and pancreatic cancer Recent Results Cancer Res 177 179 185 18084959 10.1007/978-3-540-71279-4-19 1:CAS:528:DC%2BD1cXhslSjtr0%3D
27. YM Chang L Bai S Liu JC Yang HJ Kung CP Evans 2008 Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530 Oncogene 27 49 6365 6375 10.1038/onc.2008.250 18679417 10.1038/onc.2008.250 1:CAS:528:DC%2BD1cXht1Ont7fN
28. MD Planas-Silva RD Bruggeman RT Grenko J Stanley Smith 2006 Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer Biochem Biophys Res Commun 341 1 73 81 10.1016/j.bbrc.2005.12.164 16412380 10.1016/j.bbrc.2005.12.164 1:CAS:528:DC%2BD28Xoslynsg%3D%3D (Pubitemid 43118368)
29. S Hiscox L Morgan TP Green D Barrow J Gee RI Nicholson 2006 Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 3 263 274 16333527 10.1007/s10549-005- 9120-9 1:CAS:528:DC%2BD28XmtFSitrs%3D (Pubitemid 43945756)
30. S Hiscox L Morgan T Green RI Nicholson 2006 Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr Relat Cancer 13 1 S53 S59 17259559 10.1677/erc.1.01297 1:CAS:528:DC%2BD2sXivF2mtb8%3D (Pubitemid 46222445)
31. A Myoui R Nishimura PJ Williams T Hiraga D Tamura T Michigami GR Mundy T Yoneda 2003 C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis Cancer Res 63 16 5028 5033 12941830 1:CAS:528:DC%2BD3sXms12nsb4%3D (Pubitemid 37022641)
32. MC Frame 2002 Src in cancer: deregulation and consequences for cell behaviour Biochim Biophys Acta 1602 2 114 130 12020799 1:CAS:528: DC%2BD38XjvVeitLs%3D (Pubitemid 34521791)
33. Zambuzzi WF, Milani R, Teti A (2010) Expanding the role of Src and protein tyrosine phosphatases balance in modulating osteoblast metabolism: lessons from mice. Biochimie. doi: 10.1016/j.biochi.2010.01.002
34. WF Zambuzzi R Milani A Teti 2010 Expanding the role of Src and protein-tyrosine phosphatases balance in modulating osteoblast metabolism: lessons from mice Biochimie 92 4 327 332 10.1016/j.biochi.2010.01.002 20083150 10.1016/j.biochi.2010.01.002 1:CAS:528:DC%2BC3cXivFGrtLg%3D
35. TJ de Vries MG Mullender MA van Duin CM Semeins N James TP Green V Everts J Klein-Nulend 2009 The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts Mol Cancer Res 7 4 476 488 10.1158/1541-7786.MCR-08-0219 19372577 10.1158/1541-7786.MCR-08-0219
36. W Zou H Kitaura J Reeve F Long VL Tybulewicz SJ Shattil MH Ginsberg FP Ross SL Teitelbaum 2007 Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption J Cell Biol 176 6 877 888 10.1083/jcb.200611083 17353363 10.1083/jcb.200611083 1:CAS:528:DC%2BD2sXjt1Gitb4%3D (Pubitemid 46425547)
37. T Miyazaki A Sanjay L Neff S Tanaka WC Horne R Baron 2004 Src kinase activity is essential for osteoclast function J Biol Chem 279 17 17660 17666 14739300 10.1074/jbc.M311032200 1:CAS:528:DC%2BD2cXjt1Gntbo%3D (Pubitemid 38560531)
38. X Liu R Feng 2010 Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression Acta Biochim Biophys Sin (Shanghai) 42 7 496 501 10.1093/abbs/gmq043 10.1093/abbs/gmq043 1:CAS:528:DC%2BC3cXotlCjtbo%3D
39. XH Zhang Q Wang W Gerald CA Hudis L Norton M Smid JA Foekens J Massague 2009 Latent bone metastasis in breast cancer tied to Src-dependent survival signals Cancer Cell 16 1 67 78 10.1016/j.ccr.2009.05.017 19573813 10.1016/j.ccr.2009.05.017 1:CAS:528:DC%2BD1MXhtVWnsL7I
40. DC Sgroi 2009 Breast cancer SRC activity: bad to the bone Cancer Cell 16 1 1 2 10.1016/j.ccr.2009.06.010 19573804 10.1016/j.ccr.2009.06.010 1:CAS:528:DC%2BD1MXhtVWns7fI
41. F Saad A Lipton 2010 SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer Cancer Treat Rev 36 2 177 184 10.1016/j.ctrv.2009.11.005 20015594 10.1016/j.ctrv.2009.11.005 1:CAS:528:DC%2BC3cXjtFyhsb8%3D
42. Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI (2010) Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer. doi: 10.1016/j.ejca.2010.04.012
43. Araujo J, Logothetis C (2010) Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. doi: 10.1016/j.ctrv.2010.02.015
44. RE Schweppe AA Kerege JD French V Sharma RL Grzywa BR Haugen 2009 Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer J Clin Endocrinol Metab 94 6 2199 2203 10.1210/jc.2008-2511 19293266 10.1210/jc.2008-2511 1:CAS:528:DC%2BD1MXntFGmtbo%3D
45. NV Rajeshkumar AC Tan E De Oliveira C Womack H Wombwell S Morgan MV Warren J Walker TP Green A Jimeno WA Messersmith M Hidalgo 2009 Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer Clin Cancer Res 15 12 4138 4146 10.1158/1078-0432.CCR-08-3021 19509160 10.1158/1078-0432.CCR-08-3021 1:CAS:528:DC%2BD1MXntlOisb4%3D
46. PR Purnell PC Mack CG Tepper CP Evans TP Green PH Gumerlock PN Lara DR Gandara HJ Kung O Gautschi 2009 The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells J Thorac Oncol 4 4 448 454 10.1097/JTO.0b013e31819c78fb 19240653 10.1097/JTO.0b013e31819c78fb
47. N Rucci M Susa A Teti 2008 Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases Anticancer Agents Med Chem 8 3 342 349 18393792 10.2174/187152008783961905 1:CAS:528:DC%2BD1cXkt1altr0%3D (Pubitemid 351761438)
48. S Hiscox RI Nicholson 2008 Src inhibitors in breast cancer therapy Expert Opin Ther Targets 12 6 757 767 10.1517/14728222.12.6.757 18479222 10.1517/14728222.12.6.757 1:CAS:528:DC%2BD1cXlvFSjs70%3D (Pubitemid 351877304)
49. D Lee O Gautschi 2006 Clinical development of SRC tyrosine kinase inhibitors in lung cancer Clin Lung Cancer 7 6 381 384 16800962 10.3816/CLC.2006.n.020 1:CAS:528:DC%2BD28XmsFyqt7k%3D (Pubitemid 44043546)
50. R Zheng S Yano Y Matsumori E Nakataki H Muguruma M Yoshizumi S Sone 2005 SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells Clin Exp Metastasis 22 3 195 204 16158247 10.1007/s10585-005-7768-5 1:CAS:528:DC%2BD28XlsFWjtLg%3D (Pubitemid 41298001)
51. S Bagrodia I Chackalaparampil TE Kmiecik D Shalloway 1991 Altered tyrosine 527 phosphorylation and mitotic activation of p60c-src Nature 349 6305 172 175 1702522 10.1038/349172a0 1:CAS:528:DyaK3MXlvVSnsQ%3D%3D (Pubitemid 21912040)
52. JD Bjorge A Jakymiw DJ Fujita 2000 Selected glimpses into the activation and function of Src kinase Oncogene 19 49 5620 5635 11114743 10.1038/sj.onc.1203923 1:CAS:528:DC%2BD3cXosl2nuro%3D
53. JD Bjorge TJ O'Connor DJ Fujita 1996 Activation of human pp60c-src Biochem Cell Biol 74 4 477 484 8960354 10.1139/o96-052 1:CAS:528: DyaK28XnsVKqsrc%3D
54. CA Cartwright MP Kamps AI Meisler JM Pipas W Eckhart 1989 pp60c-src activation in human colon carcinoma J Clin Invest 83 6 2025 2033 10.1172/JCI114113 2498394 10.1172/JCI114113 1:CAS:528:DyaL1MXksFGjsrw%3D (Pubitemid 19148875)
55. JA Cooper B Howell 1993 The when and how of Src regulation Cell 73 6 1051 1054 7685656 10.1016/0092-8674(93)90634-3 1:CAS:528:DyaK3sXkvV2msrY%3D (Pubitemid 23180479)
56. M Guarino 2010 Src signaling in cancer invasion J Cell Physiol 223 1 14 26 10.1002/jcp.22011 20049846 1:CAS:528:DC%2BC3cXhtlSit70%3D
57. G Superti-Furga SA Courtneidge 1995 Structure-function relationships in Src family and related protein tyrosine kinases Bioessays 17 4 321 330 7537961 10.1002/bies.950170408 1:CAS:528:DyaK2MXms12htrw%3D
58. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Ple PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. doi: 10.1016/j.molonc.2009.01.002
59. S Previdi P Maroni E Matteucci M Broggini P Bendinelli MA Desiderio 2010 Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways Eur J Cancer 46 9 1679 1691 10.1016/j.ejca.2010.02.036 20350802 10.1016/j.ejca.2010.02.036 1:CAS:528:DC%2BC3cXmslers7Y%3D
60. U Coskun N Gunel B Sancak U Gunel E Onuk O Bayram E Yilmaz S Candan S Ozkan 2003 Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients Breast 12 2 104 110 14659339 10.1016/S0960-9776(02)00214-X (Pubitemid 36546434)
61. U Coskun N Gunel FB Toruner B Sancak E Onuk O Bayram O Cengiz E Yilmaz S Elbeg S Ozkan 2003 Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer Neoplasma 50 1 41 46 12687277 1:CAS:528:DC%2BD3sXjs1entL8%3D (Pubitemid 36458939)
62. OI Ahmed AM Adel DR Diab NS Gobran 2006 Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients Egypt J Immunol 13 2 61 68 18689272
63. MS Bendre D Gaddy-Kurten T Mon-Foote NS Akel RA Skinner RW Nicholas LJ Suva 2002 Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo Cancer Res 62 19 5571 5579 12359770 1:CAS:528:DC%2BD38Xnsl2lsbo%3D
64. IH Benoy R Salgado P Van Dam K Geboers E Van Marck S Scharpe PB Vermeulen LY Dirix 2004 Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival Clin Cancer Res 10 21 7157 7162 10.1158/1078-0432.CCR-04-0812 15534087 10.1158/1078-0432.CCR-04-0812 1:CAS:528:DC%2BD2cXpsVKltLk%3D (Pubitemid 39487700)
65. R Salgado S Junius I Benoy P Van Dam P Vermeulen E Van Marck P Huget LY Dirix 2003 Circulating interleukin-6 predicts survival in patients with metastatic breast cancer Int J Cancer 103 5 642 646 10.1002/ijc.10833 12494472 10.1002/ijc.10833 1:CAS:528:DC%2BD3sXmtFKnsw%3D%3D (Pubitemid 36091468)
66. AK Sasser NJ Sullivan AW Studebaker LF Hendey AE Axel BM Hall 2007 Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer FASEB J 21 13 3763 3770 10.1096/fj.07-8832com 17586727 10.1096/fj.07-8832com 1:CAS:528:DC%2BD2sXht12jtr7K (Pubitemid 350075164)
67. GJ Zhang I Adachi 1999 Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma Anticancer Res 19 2B 1427 1432 10365118 1:STN:280:DyaK1M3ptlCmsA%3D%3D (Pubitemid 29257471)
68. PC Chan YL Chen CH Cheng KC Yu LA Cary KH Shu WL Ho HC Chen 2003 Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation J Biol Chem 278 45 44075 44082 10.1074/jbc.M305745200 12941962 10.1074/jbc.M305745200 1:CAS:528:DC%2BD3sXoslWmsbc%3D (Pubitemid 37377148)
69. L Crostella S Lidder R Williams GG Skouteris 2001 Hepatocyte growth factor/scatter factor-induces phosphorylation of cortactin in A431 cells in a Src kinase-independent manner Oncogene 20 28 3735 3745 10.1038/sj.onc.1204474 11439336 10.1038/sj.onc.1204474 1:CAS:528:DC%2BD3MXltVKnsb4%3D (Pubitemid 32624965)
70. E Matteucci E Ridolfi P Maroni P Bendinelli MA Desiderio 2007 c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor dependent decrease of CXCR4 expression in highly invasive breast tumor cells Mol Cancer Res 5 8 833 845 10.1158/1541-7786.MCR-07-0054 17699109 10.1158/1541-7786.MCR-07-0054 1:CAS:528:DC%2BD2sXptVWhsrY%3D (Pubitemid 47294811)
71. N Rahimi W Hung E Tremblay R Saulnier B Elliott 1998 c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells J Biol Chem 273 50 33714 33721 9837958 10.1074/jbc.273.50.33714 1:CAS:528:DyaK1MXis1I%3D (Pubitemid 29005761)
72. M Duval F Le Boeuf J Huot JP Gratton 2007 Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase Mol Biol Cell 18 11 4659 4668 10.1091/mbc.E07-05-0467 17855507 10.1091/mbc.E07-05-0467 1:CAS:528:DC%2BD2sXht12js7nJ (Pubitemid 350060190)
73. BP Eliceiri XS Puente JD Hood DG Stupack DD Schlaepfer XZ Huang D Sheppard DA Cheresh 2002 Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling J Cell Biol 157 1 149 160 10.1083/jcb.200109079 11927607 10.1083/jcb.200109079 1:CAS:528:DC%2BD38Xis1Knsbw%3D (Pubitemid 34847837)
74. DP Lesslie JM Summy NU Parikh F Fan JG Trevino TK Sawyer CA Metcalf WC Shakespeare DJ Hicklin LM Ellis GE Gallick 2006 Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases Br J Cancer 94 11 1710 1717 10.1038/sj.bjc.6603143 16685275 1:CAS:528:DC%2BD28XltVOmtLY%3D (Pubitemid 43924937)
75. CT Guy SK Muthuswamy RD Cardiff P Soriano WJ Muller 1994 Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice Genes Dev 8 1 23 32 7507074 10.1101/gad.8.1.23 1:CAS:528:DyaK2cXhtVelsLw%3D (Pubitemid 24032850)
76. SK Muthuswamy WJ Muller 1994 Activation of the Src family of tyrosine kinases in mammary tumorigenesis Adv Cancer Res 64 111 123 7879656 10.1016/S0065-230X(08)60836-2 1:CAS:528:DyaK2MXjslSnur8%3D (Pubitemid 24351295)
77. SK Muthuswamy PM Siegel DL Dankort MA Webster WJ Muller 1994 Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity Mol Cell Biol 14 1 735 743 7903421 1:CAS:528:DyaK2cXhtVemtLk%3D
78. GR Wilson A Cramer A Welman F Knox R Swindell H Kawakatsu RB Clarke C Dive NJ Bundred 2006 Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity Br J Cancer 95 10 1410 1414 10.1038/sj.bjc.6603444 17060931 10.1038/sj.bjc.6603444 1:CAS:528:DC%2BD28XhtF2ns7%2FL (Pubitemid 44760094)
79. Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B (2009) Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res 11 (4):R45. doi: 10.1186/bcr2332
80. B Boyer Y Bourgeois MF Poupon 2002 Src kinase contributes to the metastatic spread of carcinoma cells Oncogene 21 15 2347 2356 10.1038/sj.onc.1205298 11948418 10.1038/sj.onc.1205298 1:CAS:528: DC%2BD38XivFykurg%3D (Pubitemid 34407294)
81. J Edwards 2010 Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer Expert Opin Investig Drugs 19 5 605 614 10.1517/13543781003789388 20367532 10.1517/13543781003789388 1:CAS:528:DC%2BC3cXkvVyisrY%3D
82. B Elsberger B Stewart O Tatarov J Edwards 2010 Is Src a viable target for treating solid tumours? Curr Cancer Drug Targets 10 7 683 694 20578988 10.2174/156800910793605802 1:CAS:528:DC%2BC3cXhsVSku7nK
83. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641-651. doi: 10.1038/nrclinonc.2010.134
84. SA Eissa SA Zaki SM El-Maghraby DY Kadry 2005 Importance of serum IL-18 and RANTES as markers for breast carcinoma progression J Egypt Natl Canc Inst 17 1 51 55 16353083
85. E Azenshtein G Luboshits S Shina E Neumark D Shahbazian M Weil N Wigler I Keydar A Ben-Baruch 2002 The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity Cancer Res 62 4 1093 1102 11861388 1:CAS:528:DC%2BD38XitVSmsbc%3D (Pubitemid 34160293)
86. J Dimberg A Hugander D Wagsater 2006 Protein expression of the chemokine, CCL28, in human colorectal cancer Int J Oncol 28 2 315 319 16391784 1:CAS:528:DC%2BD28XhsFSgtLk%3D
87. Y Kawai M Kaidoh Y Yokoyama K Sano T Ohhashi 2009 Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes Cancer Sci 100 3 419 428 10.1111/j.1349-7006.2008.01064.x 19154405 10.1111/j.1349-7006.2008.01064.x 1:CAS:528:DC%2BD1MXjt1WrtLo%3D
88. KL Kroeze WJ Jurgens BZ Doulabi FJ van Milligen RJ Scheper S Gibbs 2009 Chemokine-mediated migration of skin-derived stem cells: predominant role for CCL5/RANTES J Invest Dermatol 129 6 1569 1581 10.1038/jid.2008.405 19122644 10.1038/jid.2008.405 1:CAS:528:DC%2BD1MXlslGitr4%3D
89. G Luboshits S Shina O Kaplan S Engelberg D Nass B Lifshitz-Mercer S Chaitchik I Keydar A Ben-Baruch 1999 Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma Cancer Res 59 18 4681 4687 10493525 1:CAS:528:DyaK1MXmtVKkt7w%3D (Pubitemid 29428976)
90. H Makinoshima M Dezawa 2009 Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway FEBS Lett 583 22 3697 3703 10.1016/j.febslet.2009.10.061 19874825 10.1016/j.febslet.2009.10.061 1:CAS:528:DC%2BD1MXhsVWls7rL
91. G Soria N Yaal-Hahoshen E Azenshtein S Shina L Leider-Trejo L Ryvo E Cohen-Hillel A Shtabsky M Ehrlich T Meshel I Keydar A Ben-Baruch 2008 Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions Cytokine 44 1 191 200 10.1016/j.cyto.2008.08.002 18790652 10.1016/j.cyto.2008.08.002 1:CAS:528:DC%2BD1cXhtFOmt77N
92. N Wigler S Shina O Kaplan G Luboshits S Chaitchik I Keydar A Ben-Baruch 2002 Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease Isr Med Assoc J 4 11 940 943 12455185 (Pubitemid 35291276)
93. Y Wu YY Li K Matsushima T Baba N Mukaida 2008 CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process J Immunol 181 9 6384 6393 18941229 1:CAS:528:DC%2BD1cXht1KrtrbF
94. FJ Hoar S Chaudhri MS Wadley PS Stonelake 2003 Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma Eur J Cancer 39 12 1698 1703 12888364 10.1016/S0959-8049(03)00382-4 1:CAS:528:DC%2BD3sXlvVCntbk%3D (Pubitemid 36897606)
95. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 7 1423 1431 10735889 1:CAS:528:DC%2BD3cXivVeisro%3D (Pubitemid 30205387)
96. Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 120 (2):491-498. doi: 10.1007/s10549-010-0758-6
97. C Jedeszko BC Victor I Podgorski BF Sloane 2009 Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ Cancer Res 69 23 9148 9155 10.1158/0008-5472.CAN-09-1043 19920187 10.1158/0008-5472. CAN-09-1043 1:CAS:528:DC%2BD1MXhsV2itLbP
98. S Mine T Fujisaki C Kawahara T Tabata T Iida M Yasuda T Yoneda Y Tanaka 2003 Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44 Exp Cell Res 288 1 189 197 12878170 10.1016/S0014-4827(03)00184-8 1:CAS:528:DC%2BD3sXls1OjtLk%3D (Pubitemid 36871008)
99. D Mukhopadhyay L Tsiokas XM Zhou D Foster JS Brugge VP Sukhatme 1995 Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation Nature 375 6532 577 581 7540725 10.1038/375577a0 1:CAS:528:DyaK2MXmtlajsbg%3D